Beranda › Miastenia Gravis
Uji klinis Miastenia Gravis yang merekrut di AS
45 studi untuk Miastenia Gravis merekrut peserta di lokasi di seluruh Amerika Serikat.
Kota dengan studi terbanyak
- Tampa, FL12 studi
- Houston, TX11 studi
- Durham, NC10 studi
- Boca Raton, FL10 studi
- Columbus, OH8 studi
- Milwaukee, WI7 studi
- St. Louis, MO7 studi
- Miami, FL7 studi
- New York City, NY7 studi
- Philadelphia, PA6 studi
- Columbia, MO6 studi
- Jacksonville, FL6 studi
- Washington, DC6 studi
- Chattanooga, TN6 studi
- Orange, CA6 studi
- Dallas, TX6 studi
- Boston, MA6 studi
- Austin, TX6 studi
- Charleston, SC6 studi
- Kansas City, KS6 studi
- San Francisco, CA6 studi
- Portland, OR6 studi
- Detroit, MI6 studi
- Lexington, KY5 studi
- Scottsdale, AZ5 studi
- Cincinnati, OH5 studi
- Port Charlotte, FL5 studi
- Aurora, CO5 studi
- Augusta, GA4 studi
- New Haven, CT4 studi
- Los Angeles, CA4 studi
- Mountain View, CA4 studi
- Amherst, NY4 studi
- Chicago, IL4 studi
- Knoxville, TN3 studi
- Lansing, MI3 studi
- Clearwater, FL3 studi
- Brockton, MA3 studi
- Indianapolis, IN3 studi
- Phoenix, AZ3 studi
Berdasarkan negara bagian
- Arizona7 studi
- California20 studi
- Colorado8 studi
- Connecticut6 studi
- Distrik Columbia6 studi
- Florida22 studi
- Georgia4 studi
- Illinois12 studi
- Indiana3 studi
- Kansas7 studi
- Kentucky6 studi
- Massachusetts11 studi
- Michigan12 studi
- Minnesota3 studi
- Missouri7 studi
- Nevada3 studi
- New Jersey3 studi
- New York13 studi
- North Carolina14 studi
- Ohio13 studi
- Oregon8 studi
- Pennsylvania6 studi
- South Carolina7 studi
- Tennessee10 studi
- Texas18 studi
- Virginia3 studi
- Wisconsin7 studi
Studi yang baru diperbarui
Teks studi resmi (Bahasa Inggris)
Feasibility of Remote Monitoring of Patients With Myasthenia Gravis
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT07787247A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07463521Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis
Menerima pesertaFase 3
Usia 18 hingga 74 · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07217587A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)
Menerima pesertaFase 3
Usia 18 hingga 80 · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07647510ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT07673627ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT07294170A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT07465289ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT07284420A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07673744Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT06463587A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Sep 2026 · NCT07501702A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Sep 2026 · NCT06680037A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)
Menerima pesertaFase 2
Usia 2 hingga 17 · Semua jenis kelamin · Diperbarui 1 Sep 2026 · NCT06987539Zilucoplan for Severe gMG Exacerbations
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Agu 2026 · NCT07215949Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 21 Agu 2026 · NCT06414954AXIS MG Patient Registry
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Agu 2026 · NCT07761026A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases
Menerima pesertaFase 1
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 14 Agu 2026 · NCT07304154RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
Menerima pesertaFase 1/2
Usia 18 hingga 70 · Semua jenis kelamin · Diperbarui 13 Agu 2026 · NCT06359041Pregnancy Registry, Infants, Serum/Milk Analysis (PRISMA)
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 18 hingga 64 · Wanita · Diperbarui 11 Agu 2026 · NCT06940323MuSK Myasthenia 1000 Study
Menerima pesertaStudi observasional
Usia 7 hingga 99 · Semua jenis kelamin · Diperbarui 5 Agu 2026 · NCT06259071Study of Aritinercept in Patients With Generalized Myasthenia Gravis
Menerima pesertaFase 1/2
Usia 18 hingga 85 · Semua jenis kelamin · Diperbarui 3 Agu 2026 · NCT07596901A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis
Menerima pesertaFase 2/3
Usia 2 hingga 17 · Semua jenis kelamin · Diperbarui 31 Jul 2026 · NCT05265273Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
Menerima pesertaFase 3
Usia 18 hingga 80 · Semua jenis kelamin · Diperbarui 30 Jul 2026 · NCT07039916KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
Menerima pesertaFase 2/3
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 29 Jul 2026 · NCT06193889A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 27 Jul 2026 · NCT04951622Dari ClinicalTrials.gov, data diambil 4 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.